Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa kolutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
The prevalence of non-alcoholic fatty liver disease (NAFLD) and its progression to the more serious non-alcoholic steatohepatitis (NASH) are increasing globally. The rising NAFLD/NASH prevalance is closely linked to the rising global obesity and type 2 diabetes epidemics. These are currently no approved therapeutics for the management of NAFLD/NASH. Disease is generally managed with lifestyle modicifaction including diet and excercise. As a result it is critical to identify NAFLD early in patiens to minimize progression to NASH, cirrhosis, and eventually hepatocellular carcinoma. This curriculum will highlight NASH as a metabolic disorder and will empasize the need for early detection, risk assessment, and treatment to prevent progression of this rising epidemic.
Made for: Gastroenterologists, Diabetoligists, Endocrinologists
Disease areas: Non-Alcoholic Steatohepatitis
Developed by: Medscape Education Global
